Home
Live Updates
StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy : vimarsana.com
StockWatch: Apellis Wows Analysts with First FDA Approval for GA Therapy
Nine analysts raise stock price targets for Apellis Pharmaceuticals after it wins the FDA's first approval for a geographic atrophy therapy.
Related Keywords
,
Peter Stein ,
Raymond James ,
Iveric Bio ,
Annabel Samimy ,
Steven Seedhouse ,
Yigal Nochomovitz ,
Robertw Baird ,
Laura Chico ,
Chris Howerton ,
Chirinjeev Kathuria ,
Doug Tsao ,
Colleen Kusy ,
Tazeen Ahmad ,
Jackk Allen ,
Brian Culley ,
Ib Chemoprotection ,
Office Of New Drugs ,
Genentech ,
Apellis Pharmaceuticals ,
Goldman Sachs ,
Evercore Group ,
Citigroup ,
Approval Commences ,
New Era ,
New Drug Application ,
Priority Review ,
Prescription Drug User Fee Act ,
Bofa Securities ,
Lineage Cell Therapeutics ,
Phase Ib Chemoprotection ,
Formal Dispute Resolution Request ,
Complete Response Letter ,
New Drugs ,
vimarsana.com © 2020. All Rights Reserved.